GSK plc reports first quarter 2026 financial results
GSK plc reported its first quarter 2026 financial results, with total sales increasing by 5% to £7.6 billion. Specialty medicines and Shingrix were key growth drivers.
London, UK – GSK plc announced its first quarter 2026 financial results on April 29, 2026, revealing a 5% year-on-year increase in total sales, reaching £7.6 billion.
The company's performance was bolstered by strong growth in specialty medicines, which saw a 14% increase to £3.2 billion. Vaccines contributed £2.3 billion, though this segment experienced a 6% decline.
Key products driving sales included Shingrix, generating £1,026 million (a 20% increase), and Jemperli, with sales of £232 million (a 40% increase). Nucala's sales reached £484 million, marking a 12% rise, particularly driven by its launch in the COPD indication.
GSK reaffirmed its 2026 guidance, projecting sales growth of 3-5% and core operating profit and core EPS growth of 7-9%. The company stated its strategic focus remains on accelerating growth, enhancing R&D, and simplifying operations.